Drug treatment for endometriosis-related pain

1. Santali Р., Tran С., Gayet V., Bourdon M., Maignien C., Marcellin L. et al. Oligo-anovulation is not a rarer feature in women with documented endometriosis. Fertil. Steril. 2018; 110(5): 941-8.
2. Saridogan E. Adolescent endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 209: 46-9.
3. De Sanctis V., Matalliotakis M., Soliman A., Elsefdy H., Di Maio S., Fiscina B. A focus on the distinctions and current evidence of endometriosis in adolescents. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 15: 138-50.
4. Moggio A., Pittatore G., Cassoni P., Marchino G.L., Revelli A., Bussolati B. Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertil. Steril. 2012; 98(6): 1521-30.
5. Albertsen H.M., Ward K. Genes linked to endometriosis by GWAS are integral to cytoskeleton regulation and suggests that mesothelial barrier homeostasis is a factor in the pathogenesis of endometriosis. Reprod. Sci. 2016; Jul 28. pii: 1933719116660847.
6. Vercellini P., Buggio L., Frattaruolo M.P., Borghi A., Dridi D., Somigliana E. Medical treatment of endometriosis-related pain. Best Pract. Res. Clin. Obstet. Gynaecol. 2018; 51: 68-91. doi: 10.1016/j.bpobgyn.2018.01.015.
7. Santulli P., Marcellin L., Menard S., Thubert T., Khoshnood B., Gayet V. et al. Increased rate of spontaneous miscarriages in endometriosis-affected women. Hum. Reprod. 2016; 31(5): 1014-23.
8. Jensen J., Schlaff W., Gordon К. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil. Steril. 2018; 110(1): 137-52. e1.
9. Harada T., Kosaka S., Elliesen J., Yasuda M., Ito M., Momoeda M. Ethinylestradiol 20 mg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil. Steril. 2017; 108(5): 798-805.
10. Vercellini P., Somigliana E., Vigano P., Abbiati A., Barbara G., Fedele L. ‘‘Blood on the tracks’’ from corpora lutea to endometriomas. BJOG. 2009; 116(3): 366. e71.
11. National Institute for Health and Care Excellence. Endometriosis: diagnosis and management. NICE guideline NG73. September, 2017. Available at: https://www.nice.org.uk/guidance/ng73/evidence/full-guideline-pdf-4550371315 Accessed 3 November, 2017
12. Flores V.A., Vanhie A., Dang T., Taylor H.S. Progesterone receptor status as a predictor of response to progestins in endometriosis. Fertil. Steril. 2018; 110(4, Suppl.): e383.
13. Vercellini Р., Ottolinia F., Frattaruolo М.Р., Buggio L., Roberto А., Somigliana Е. Shifting from oral contraceptives to norethisterone acetate, or vice versa, because of drug intolerance: does the change benefit women with endometriosis? Gynecol. Obstet. Invest. 2018; 83(3): 275-84. DOI: 10.1159/000486335
14. Miller J., Missmer S., Vitonis А., Sarda V., Laufer M., Di Vasta А. Prevalence of migraines in adolescents with endometriosis. Fertil. Steril. 2018; 109(4): 685-90.
15. Chapron C., Souza C., Borghese B., Lafay-Pillet M.C., Santulli P., Bijaoui G. et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum. Reprod. 2011; 26(8): 2028-35.
16. Casper R.F. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil. Steril. 2017; 107(3): 533-6.
17. Дубровина С.О., Берлим Ю.Д. Гестагены в терапии эндометриоза. Акушерство и гинекология. 2018; 5: 150-5. [Dubrovina S.O., Berlim Yu.D. Progestins in the treatment of endometriosis. Obstetrics and gynecology. 2018; 5: 150-5. (in Russian)]
18. Министерство Здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. М.; 2016. ID: КР259. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. M .; 2016. ID: KR259. (in Russian)]
19. Приказ Минздрава России от 01.11.2012 N 572н (ред. от 12.01.2016) «Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)» (Зарегистрировано в Минюсте России 02.04.2013 N 27960). [Order of the Ministry of Health of Russia of November 1, 2012 No. 572n (ed. Of January 12, 2016) “On approval of the Procedure for rendering medical assistance in the profile «obstetrics and gynecology (except for the use of assisted reproductive technologies)» (Registered in the Ministry of Justice of Russia April 2, 2013 27960).(in Russian)]
20. Vercellini P., Pietropaolo G., De Giorgi O., Pasin R., Chiodini A., Crosignani P.G. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil. Steril. 2005; 84(5): 1375-87.
21. Chwalisz K., Surrey E., Stanczyk F.Z. The hormonal profile of norethindroneacetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod. Sci. 2012; 19(6):563-71.
22. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., Thijssen J.H. Classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171-80.
23. Africander D., Verhoog N., Hapgood J.P. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011; 76(7): 636-52.
24. Ebert A.D., Dong L., Merz M., Kirsch B., Francuski M., Bottcher B. et al. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis: the VISanne study to assess safety in adolescents. J. Pediatr. Adolesc. Gynecol. 2017; 30(5): 560. e7.
25. Momoeda M., Harada T., Terakawa N., Aso T., Fukunaga M., Hagino H., Taketani Y. Long-term use of dienogest for the treatment of endometriosis. J. Obstet. Gynaecol. Res. 2009; 35(6): 1069-76.
26. Petraglia F., Hornung D., Seitz C., Faustmann T., Gerlinger C., Luisi S. et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch. Gynecol. Obstet. 2012; 285(1):167-73.
27. Kim S.A., Um M.J., Kim H.K., Kim S.J., Moon S.J., Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet. Gynecol. Sci. 2016; 59(6): 506-11.
28. Jeonga S.H., Lee D., Kim S.K., Jee B.C. Symptom-alleviating effect and adverse effect of dienogest in Korean women with endometriosis. Gynecol. Endocrinol. 2018; 34(11): 970-4.
29. Kohler G., Faustmann T.A., Gerlinger C., Seitz C., Mueck A.O. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis. Int. J. Gynaecol. Obstet. 2010; 108: 21-5.
30. Strowitzki T., Marr J., Gerlinger C., Faustmann T., Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum. Reprod. 2010; 25(3): 633-41.
31. Kitawaki J., Ishihara H., Kiyomizu M., Honjo H. Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Fertil. Steril. 2008; 89(6): 1831-5.
32. Kitawaki J., Kusuki I., Yamanaka K., Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 157: 212-6.
33. Somigliana E., Vercellini P., Vigano P., Benaglia L., Busnelli A., Fedele L. Postoperative medical therapy after surgical treatment of endometriosis: from adjuvant therapy to tertiary prevention. J. Minim. Invasive Gynecol. 2014; 21(3): 328. e34.
34. Di Francesco A., Pizzigallo D. Use of micronized palmitoylethanolamide and transpolydatin in chronic pelvic pain associated with endometriosis. An open-label study. Giorn. Ital. Ostetr. Ginecol. 2014; 36: 353-8.
35. Vercellini P., de Giorgi O., Mosconi P., Stellato G., Vicentini S., Crosignani P.G. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil. Steril. 2002; 77: 52-61.
36. Zupi E., Marconi D., Sbracia M., Zullo F., de Vivo B., Exacustos C. et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil. Steril. 2004; 82(5): 1303-8.
37. Liang B., Wu L., Xu H., Cheung C.W., Fung W.Y., Wong S.W., Wang C.C. Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice. Reprod. Biol. Endocrinol. 2018; 16(1): 32. DOI: 10.1186/s12958-018-0347-9
38. Дубровина С.О., Берлим Ю.Д., Арешан К.А., Гаджибекова Н.Б. Сравнительная характеристика эутопического и эктопического эндометрия при эндометриоидных кистах яичников с нормальным эндометрием. Проблемы репродукции. 2018; 24(6): 108-12. Doi: 10.17116/repro201824061108. [Dubrovina S.O., Berlim Yu.D., Areshan K.A., Gadzhibekova N.B. Comparative characteristics of eutopic and ectopic endometrium in endometrioid ovarian cysts with normal endometrium. Reproduction problems. 2018; 24 (6): 108-12. Doi: 10.17116/repro201824061108. (in Russian)]
39. Mönckedieck V., Sannecke C., Husen B., Kumbartski M., Kimmig R., Tötsch M. et al. Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model. Mol. Hum. Reprod. 2009; 15(10): 633-43. doi: 10.1093/molehr/gap063.
40. Bulun S.E., Cheng Y.H., Pavone M.E., Yin P., Imir G., Utsunomiya H. et al. 17b-Hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. Semin. Reprod. Med. 2010; 28: 44-50.
41. Vercellini P., Buggio L., Berlanda N., Barbara G., Somigliana E., Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil. Steril. 2016; 106(7): 15520-71.
42. Подзолкова Н.М., Татарчук Т.Ф., Дощанова А.М., Ешимбетова Г.З., Сумятина Л.В. Нормализация менструального цикла дидрогестероном. Акушерство и гинекология. 2018; 6: 70. [Podzolkova N.M., Tatarchuk T.F., Doschanova A.M., Eshimbetova G.Z., Sumyatina L.V. Normalization of the menstrual cycle didrogesterone. Obstetrics and gynecology. 2018; 6:20.(in Russian)]
43. Сухих Г.Т., Адамян Л.В., Серов В.Н., Андреева Е.Н., Баранов И.И., Дубровина С.О., Козаченко А.В., Кулешов В.М., Подзолкова Н.М., Прилепская В.Н., Радзинский В.Е., Сонова М.М., Тихомиров А.Л., Уварова Е,В.,Чернуха Г.Е., Ших Е.В., Ярмолинская М.И. Резолюция совещания экспертов на тему «Возможности персонализации гормональной терапии эндометриоза с использованием препарата дидрогестерон. Утверждение протокола многоцентрового открытого наблюдательного исследования по применению дидрогестерона для лечения эндометриоза в России (исследование «ОРХИДЕЯ»)». Проблемы репродукции. 2018; 24(5): 41-4. https://doi.org/10.17116/repro20182405141. [Sukhikh G.T., Adamyan L.V., Serov V.N., Andreeva E.N., Baranov I.I., Dubrovina S.O., Kozachenko A.V., Kuleshov V.M., Podzolkova N.M., Prilepskaya V.N., Radzinsky V.E., Sonova M.M., Tikhomirov A.L., Uvarova E.V., Chernukha G.E., Shikh E.V., Yarmolinskaya M .AND. The resolution of the expert meeting on the topic «Possibilities of personalizing the hormonal therapy of endometriosis using the didrogesterone drug. Approval of the protocol of a multicenter open observational study on the use of didrogesterone for the treatment of endometriosis in Russia (research «ORCHID»)». Reproduction problems. 2018; 24 (5): 41-4. (in Russian)]
44. Государственный реестр лекарственных средств. Инструкция по медицинскому применению препарата Дюфастон от 26.07.2017. [The state register of medicines. Instructions for medical use of the drug Duphaston from 07.26.2017. (in Russian)]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3ee36e24-2022-40d7-9f6c-7d699a196f50&t Accessed 01.02.2019.
45. Тетруашвили Н.К., Агаджанова А.А. Дидрогестерон в лечении угрожающего и привычного выкидыша. Медицинский совет. 2018; 13: 34-8. [Tetruashvili N.K., Agadzhanova A.A. Didrogesteron in the treatment of threatening and habitual miscarriage. Medical advice. 2018; 13: 34-8. (in Russian)]

Received 15.02.2019

Accepted 22.02.2019